Umeclidinium Bromide/Vilanterol Trifenatate

乌美溴铵/三苯乙酸维兰特罗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameUmeclidinium Bromide/Vilanterol Trifenatate
Drug Alias Name芜地溴铵/Vilanterol TrifenatateVilanterol Trifenatate and Umeclidinium BromideVilanterol Trifenatate/Umeclidinium BromideUmeclidinium Bromide and Vilanterol TrifenatateUmeclidinium bromide/vilanterol +[13] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonistsBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor M4 antagonists +[6] 
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor M2Muscarinic acetylcholine receptor M1 +[6] 
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryUnited States
Original Approved Date2013/12/18
Country/TerritoryCzechiaBulgariaCanada +[23] 
CombinationsYes Umeclidinium BromideVilanterol Trifenatate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd
Inactive CompaniesGlaxo Group LtdGlaxo Operations Uk LtdGlaxosmithkline (China) Investment Co Ltd
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeR03AL03
Related LinksWikipediaKEGG